-
Product Insights
Likelihood of Approval Analysis for Alopecia Areata
Overview How likely is it that the drugs in Alopecia Areata will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Alopecia Areata Overview Alopecia areata is an autoimmune condition characterized by unpredictable,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lepzacitinib in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lepzacitinib in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lepzacitinib in Atopic Dermatitis (Atopic Eczema) Drug Details: ATI-1777 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CS-12192 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CS-12192 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CS-12192 in Graft Versus Host Disease (GVHD) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Deucravacitinib in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deucravacitinib in Sicca Syndrome (Sjogren) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deucravacitinib in Sicca Syndrome (Sjogren) Drug Details: Deucravacitinib (Sotyktu) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Alopecia Areata Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Asthma Drug Details: Amlitelimab (SAR445229) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Hidradenitis Suppurativa Drug Details: Amlitelimab (SAR445229) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Amlitelimab (SAR445229)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Deucravacitinib in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Deucravacitinib in Alopecia Areata report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Deucravacitinib in Alopecia Areata Drug Details: Deucravacitinib (Sotyktu) is a deuterium first-in-class molecule,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dupilumab in Grass Pollen Allergy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dupilumab in Grass Pollen Allergy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dupilumab in Grass Pollen Allergy Drug Details: Dupilumab (REGN-668, SAR231893, Dupixent,...